Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsAustralia's CSL is betting big on rare diseases. The biotech giant has inked a deal worth up to $1.6 billion with Swiss firm Alentis Therapeutics to co-develop lixudebart, a potential first-in-class treatment for rare kidney and liver diseases. The drug, which holds FDA orphan status, is currently in Phase 2 trials for a rare autoimmune kidney condition that can lead to end-stage renal disease.
Australia's CSL is making a major rare disease bet. The biotech giant has signed a co-development and co-promotion agreement with Swiss drugmaker Alentis Therapeutics for lixudebart, a potential first-in-class therapy targeting rare kidney and liver diseases. The deal is valued at up to $1.6 billion (excluding development funding), with CSL paying $355 million upfront and Alentis eligible for up to $1.2 billion in commercial milestone payments.
Lixudebart is currently in a Phase 2 trial for a rare autoimmune kidney disease that can cause irreversible kidney damage and progress to end-stage renal disease. The FDA granted the drug orphan status in 2024, a designation designed to incentivize development of treatments for rare conditions. If commercialized, global profits will be split 55% to CSL and 45% to Alentis.
By the Numbers:
Why it matters: The deal signals growing industry momentum around rare disease therapeutics, particularly for conditions with limited treatment options. For CSL — which has faced investor pressure amid job cuts, earnings downgrades, and a delayed vaccine unit spin-off — lixudebart represents a meaningful pipeline addition, though analysts caution it may not be enough to dramatically shift the company's long-term growth trajectory.
